Neoadjuvant mFOLFIRINOX Provides OS Benefit in Borderline Resectable Pancreatic Cancer
Matthew H. G. Katz, MD, sheds light on the phase 2 A021501 trial (NCT02839343), which showed that neoadjuvant mFOLFIRINOX provided a favorable overall survival benefit in patients with borderline resectable pancreatic ductal adenocarcinoma when administered prior to pancreatectomy.
Neoadjuvant mFOLFIRINOX induced favorable overall survival results for patients with borderline resectable pancreatic ductal adenocarcinoma when administered prior to pancreatectomy, though neoadjuvant mFOLFIRINOX followed by hypofractionated radiation therapy did not prove to be similarly effective.
Katz Considers the Role of Neoadjuvant Chemoradiation in Borderline Resectable Pancreatic Cancer
August 11th 2022Dr Katz discusses the implications of a recently published phase 2 study investigating neoadjuvant mFOLFIRINOX with or without hypofractionated radiation therapy results for patients with borderline resectable pancreatic ductal adenocarcinoma.
Dr. Katz on Neoadjuvant mFOLFIRINOX in Pancreatic Cancer
August 11th 2022Matthew H. G. Katz, MD, CMQ, FACS, FASCO, discusses the efficacy of mFOLFIRINOX, a chemotherapy regimen consisting of oxaliplatin, irinotecan, leucovorin, and fluorouracil, prior to pancreatectomy in patients with borderline resectable pancreatic cancer.
